

No. 31026/16/2020-Policy  
Government of India  
Ministry of Chemicals & Fertilizers  
Department of Pharmaceuticals

\*\*\*\*\*

Kartavya Bhawan 2, New Delhi  
Dated 4<sup>th</sup> May, 2026

**CORRIGENDUM/ADDENDUM**

Subject: Modifications in the guidelines of Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs)/ Drug Intermediates and Active Pharmaceutical Ingredients (APIs) in India (commonly referred as “*PLI Scheme for Bulk Drugs*”)- reg.

Department of Pharmaceuticals issued Notification guidelines of the PLI Scheme for Bulk Drugs on 18.7.2020, which got revised on 29.10.2020, 26.7.2022, 12.3.2024 and 25.9.2024.

2. Based on the decision taken in the Empowered Committee meeting held on 12.3.2026, following amendments in the PLI Scheme for Bulk Drugs guidelines of 29.10.2020 are hereby notified:

<b>Existing Clause 15.4</b>	<b>Revised Clause 15.4</b>	<b>Remarks</b>
Claims for disbursement of incentive shall be filed by applicants within 9 months from the end of the financial year to which the claim pertains.	Claims for disbursement of incentive shall be filed by applicants within 9 months from the end of the financial year to which the claim pertains.	<b>No Change</b>
	<p>In case of incentive claims filed based on <b><i>management certified/ unaudited financial statements or without filing of annual return</i></b>, 80% of the eligible incentive shall be disbursed.</p> <p>The remaining 20% shall be disbursed after submission of audited financial statements with auditor’s certificate and reconciliation with annual regulatory return filings.</p> <p>Claims for disbursement of 20% incentive shall be filed by applicants <b><i>within 10 months from the end of the financial year to which the claim pertains.</i></b></p>	<b>Additional Clause</b>

Existing Clause 15.12	Revised Clause 15.12	Remarks
Applicants shall be required to reconcile sales of eligible products, based on which claims for disbursement of incentive have already been filed, with documents as prescribed by the PMA, by 31st of December of the financial year subsequent to which the claim pertains.	Applicants shall be required to reconcile sales of eligible products, based on which claims for disbursement of incentive have already been filed, with documents as prescribed by the PMA, by <b>31st of January</b> of the financial year subsequent to which the claim pertains.	<b>Amended Clause</b>

3. All other Clauses in the PLI Scheme for Bulk Drugs guidelines dated 29.10.2020 and 26.7.2022 remain the same.
4. This issues with the approval of the competent authority.

(Dharmendra Kumar Yadav)  
Under Secretary to the Government of India  
Tel: 23062531  
Email: US-PharmaSchemes@pharma-dept.gov.in

To:

1. Director (Advisory Services), IFCI Limited, IFCI Tower, 61, Nehru Place, New Delhi – 110 019, for further necessary action.
2. Head of Group, Department of Pharmaceuticals Informatics Division, National Informatics Centre — with a request to upload this notice on the website of the Department of Pharmaceuticals